Aquestive Therapeutics, Inc. (AQST)
4.61
+0.04
(+0.88%)
USD |
NASDAQ |
Oct 06, 16:00
4.61
0.00 (0.00%)
Pre-Market: 20:00
Aquestive Therapeutics Gross Profit Margin (Quarterly) : 70.93% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 70.93% |
| March 31, 2026 | 75.99% |
| December 31, 2025 | 55.16% |
| September 30, 2025 | 64.82% |
| June 30, 2025 | 54.40% |
| March 31, 2025 | 58.12% |
| December 31, 2024 | 61.91% |
| September 30, 2024 | 67.24% |
| June 30, 2024 | 77.48% |
| March 31, 2024 | 63.59% |
| December 31, 2023 | 64.57% |
| September 30, 2023 | 63.10% |
| June 30, 2023 | 50.03% |
| March 31, 2023 | 57.45% |
| December 31, 2022 | 49.59% |
| September 30, 2022 | 59.65% |
| June 30, 2022 | 60.48% |
| March 31, 2022 | 65.66% |
| December 31, 2021 | 69.62% |
| Date | Value |
|---|---|
| September 30, 2021 | 66.88% |
| June 30, 2021 | 70.90% |
| March 31, 2021 | 75.21% |
| December 31, 2020 | 61.00% |
| September 30, 2020 | 63.95% |
| June 30, 2020 | 83.67% |
| March 31, 2020 | 58.25% |
| December 31, 2019 | 58.63% |
| September 30, 2019 | 62.61% |
| June 30, 2019 | 51.30% |
| March 31, 2019 | 72.27% |
| December 31, 2018 | 71.55% |
| September 30, 2018 | 57.85% |
| June 30, 2018 | 64.29% |
| March 31, 2018 | 75.93% |
| December 31, 2017 | 53.96% |
| September 30, 2017 | 82.02% |
| June 30, 2017 | 53.86% |
| March 31, 2017 | 74.54% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | 94.90% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -56.47% |
| Return on Invested Capital | -83.54% |
| Profit Margin (Quarterly) | -165.5% |
| Operating Margin (Quarterly) | -59.50% |
| Return on Net Operating Assets | -315.6% |